| Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals L Peters, K Laut, C Resnati, S Del Campo, C Leen, K Falconer, ... Aids 32 (14), 1995-2004, 2018 | 33 | 2018 |
| Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF D Cattaneo, D Minisci, S Baldelli, C Mazzali, A Giacomelli, L Milazzo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 77 (1), 86-92, 2018 | 28 | 2018 |
| Binding motif of ebselen in solution: Chalcogen and hydrogen bonds team up A Daolio, P Scilabra, ME Di Pietro, C Resnati, K Rissanen, G Resnati New Journal of Chemistry 44 (47), 20697-20703, 2020 | 25 | 2020 |
| Effect of legal status on the early treatment outcomes of migrants beginning combined antiretroviral therapy at an outpatient clinic in Milan, Italy AL Ridolfo, L Oreni, P Vassalini, C Resnati, G Bozzi, L Milazzo, S Antinori, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 75 (3), 315-321, 2017 | 18 | 2017 |
| Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy M Franzetti, F Adorni, L Oreni, L Van Den Bogaart, C Resnati, L Milazzo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 67 (5), 493-498, 2014 | 18 | 2014 |
| The risk for malignancy using the Milan salivary gland classification categories: a 5-year retrospective review CA Liang, J Liu, JT Ogunniyi, H Zhu, S Zhang Cytojournal 16, 2019 | 15* | 2019 |
| Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction? D Cattaneo, C Resnati, G Rizzardini, C Gervasoni Aids 32 (4), 532-533, 2018 | 14 | 2018 |
| Abacavir-induced liver toxicity MD Pezzani, C Resnati, V Di Cristo, A Riva, C Gervasoni Brazilian Journal of Infectious Diseases 20 (5), 502-504, 2016 | 14 | 2016 |
| Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: potential implications for clinical practice D Cattaneo, S Baldelli, C Resnati, A Giacomelli, P Meraviglia, D Minisci, ... The World Journal of Biological Psychiatry, 2020 | 12 | 2020 |
| Correlation between inner retinal layer thickness and cognitive function in HIV: new insights from an exploratory study A Invernizzi, A Acquistapace, S Bochicchio, C Resnati, S Rusconi, ... Aids 32 (11), 1485-1490, 2018 | 12 | 2018 |
| Prolonged inductive effect of rifampicin on linezolid exposure C Gervasoni, FR Simonetti, C Resnati, N Charbe, E Clementi, D Cattaneo European journal of clinical pharmacology 71, 643-644, 2015 | 12 | 2015 |
| New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: much more than antioxidants M Cataldi, V Citro, C Resnati, F Manco, G Tarantino Advances in Therapy 38 (5), 2094-2113, 2021 | 11 | 2021 |
| Darunavir population pharmacokinetic model based on HIV outpatient data A Daskapan, QTD Tran, D Cattaneo, C Gervasoni, C Resnati, Y Stienstra, ... Therapeutic drug monitoring 41 (1), 59-65, 2019 | 11 | 2019 |
| The relevance of drug–drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration C Gervasoni, C Resnati, T Formenti, A Fossati, D Minisci, P Meraviglia, ... Antiviral Therapy 23 (5), 467-469, 2018 | 9 | 2018 |
| Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment–Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study M Poliseno, M Mazzitelli, A Narducci, SM Ferrara, C Resnati, C Gervasoni, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 94 (3), 235-243, 2023 | 5 | 2023 |
| Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens D Cattaneo, M Fusi, V Micheli, C Resnati, P Meraviglia, MV Cossu, ... AIDS 35 (15), 2551-2553, 2021 | 5 | 2021 |
| The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir C Gervasoni, D Cattaneo, C Resnati, D Pezzani, A Riva European Journal of Clinical Pharmacology 73, 789-790, 2017 | 5 | 2017 |
| Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient D Cattaneo, S Sollima, N Charbe, C Resnati, E Clementi, C Gervasoni European journal of clinical pharmacology 72, 365-367, 2016 | 3 | 2016 |
| Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons. D Cattaneo, A Fossati, C Resnati, M Galli, C Gervasoni AIDS reviews 19 (3), 2017 | 2 | 2017 |
| Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label … D Cattaneo, MV Cossu, S Fucile, A Riva, S Baldelli, P Meraviglia, ... Therapeutic Drug Monitoring 37 (1), 119-125, 2015 | 2 | 2015 |
